{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:50:09Z","timestamp":1791409809929,"version":"4.3.3"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.oret.2026.08.021","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:42Z","timestamp":1791406842000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Hong et al.: Ocular Outcomes with Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes (Ophthalmol Retina. 2026;10:625\u2013632)"],"prefix":"10.1016","author":[{"given":"Xin","family":"Guang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2026.08.021_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.oret.2026.02.002","article-title":"Ocular outcomes with tirzepatide versus glucagon-like peptide-1 receptor agonists in type 2 diabetes","volume":"10","author":"Hong","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2026.08.021_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/bimj.70094","article-title":"Pseudo-observation approach for length-biased Cox proportional hazards model","volume":"67","author":"Akbari","year":"2025","journal-title":"Biometrical Journal"},{"key":"10.1016\/j.oret.2026.08.021_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/jdr\/7203748","article-title":"Role of systemic factors in the progression to vision-threatening diabetic retinopathy in a new Mexican patient population with type 2 diabetes: glycemic control is not enough","volume":"2026","author":"Mankad","year":"2026","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.oret.2026.08.021_bib4","article-title":"Artificial intelligence in neuro-ophthalmology: opportunities for the diagnosis of optic neuropathies and visual pathway disorders","volume":"17","author":"Karkhur","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.oret.2026.08.021_bib5","doi-asserted-by":"crossref","DOI":"10.59717\/j.xinn-med.2026.100187","article-title":"Addressing confounders in observational comparative effectiveness research: methods, software, and reporting standards","volume":"4","author":"Wang","year":"2026","journal-title":"The Innovation Medicine"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026004276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653026004276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:00:44Z","timestamp":1791406844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653026004276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":5,"alternative-id":["S2468653026004276"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2026.08.021","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Hong et al.: Ocular Outcomes with Tirzepatide versus Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes (Ophthalmol Retina. 2026;10:625\u2013632)","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2026.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}